Cited 0 times in
Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.